Germany: Time for more medical device SPCs?

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Germany: Time for more medical device SPCs?

The ultimate purpose of a Supplementary Protection Certificate (SPC) is to compensate a patentee for the time lost due to lengthy regulatory approval processes.

The EU legislation governing SPCs does not explicitly cover medical devices, but only pharmaceuticals and crop protection products. One reason for this may be that medical devices only undergo a rather lean approval process that is merely supervised by a notified body instead of a regulatory authority. Consequently, there have been only exceptional cases where patentees obtained an SPC for a medical device in some EU member states. Most requests are denied.

In May 2017, the new Medical Device Regulation (MDR) and In vitro Diagnostic Medical Device Regulation (IVDMDR) entered into force. There seems to be a general consensus that the Regulations will raise the bar for market approval of medical devices. For example, the Regulations establish a new pre-market scrutiny mechanism, including a pool of experts, that ensures stricter ex-ante control for high-risk devices. One unintended consequence could be that the new Regulations will slow down market approval for medical devices, prompting even more manufacturers to reach for an SPC as compensation.

The ever-growing field of precision medicine, i.e. administration of the most suitable drug for each individual patient, promises improved medical treatments in the future. A crucial aspect of precision medicine is the use of companion diagnostics, defined according to the IVDMDR as a medical device essential for the safe and effective use of a corresponding medicinal product. Before granting market approval for companion diagnostics, the notified body shall "consult" a competent regulatory authority, which could potentially complicate and slow down the approval process.

Further, for highly innovative first-in-class drugs, the companion diagnostic will ideally be co-developed together with the drug, since its early use for patient stratification in clinical trials facilitates monitoring the effects of the new drug. However, the commercial value of the co-developed companion diagnostic is entirely dependent on regulatory approval of the first-in-class drug. It would thus be fair to not only award an SPC for the first-in-class drug but also for its companion diagnostic.

In summary, the regulatory hurdles for the market approval of many medical devices are being set higher, and we may see more cases where an SPC for medical devices may seem reasonable and just (despite medical devices not being explicitly covered by the current SPC regulations). Especially for the emerging field of precision medicine, it remains to be seen if and how the time loss due to regulatory processes can be compensated for and whether SPCs for companion diagnostics could play a part in that compensation.

Jan van Dieck


Maiwald Patentanwalts GmbHElisenhof, Elisenstr 3D-80335, Munich, GermanyTel: +49 89 74 72 660 Fax: +49 89 77 64 24info@maiwald.euwww.maiwald.eu

more from across site and SHARED ros bottom lb

More from across our site

In the wake of controversy surrounding Banksy’s recent London mural, AJ Park’s Thomas Huthwaite and Eloise Calder delve into the challenges street artists face in protecting their works and rights
Alex Levkin, founder of iPNOTE, discusses reshaping the filing industry through legal tech, and why practitioners’ advice should stretch beyond immediate legal needs
Cohausz & Florack, together with Krieger Mes & Graf von der Groeben, have taken action against Amazon on behalf of three VIA LA licensors
In the fourth episode of a podcast series celebrating the tenth anniversary of IP Inclusive, we discuss unconscious bias in the IP workplace and how to address it
Greg Munt, who has moved from Griffith Hack to James & Wells after four decades, hails his new firm’s approach to client service
Practitioners warn that closing the Denver regional office could trigger a domino effect, threatening local innovation and access to IP resources
Law firms are rethinking litigation strategies after USPTO director John Squires said he would take control of PTAB challenges
News of Singapore planning to streamline the licensing framework for foreign law firms and a partnership between Avanci and Xprize were also among the top talking points
In major recent developments, the court also ruled on another request concerning access to documents and appointed a new panel to the Court of Appeal
A new foundation in Chile is giving women in the IP community the mentorship, and visibility they’ve long lacked
Gift this article